Lexaria Bioscience

Major drug makers are in a global race — not just to create the next breakthrough weight-loss pill, but to make it safer. That’s where @LexariaBioCorp stands out. In a recent clinical study, the company’s patented oral delivery technology cut adverse events by up to 50% — a meaningful step toward more tolerable, next-gen weight-management drugs. Instead of building a single therapy, Lexaria is developing a platform: a technology that enhances absorption and may improve how future oral medications behave in the body, without changing the drug itself. As demand surges for safer, effective metabolic treatments, Lexaria is positioning its technology as a potential upgrade layer for an entire class of next-generation therapies. Lexaria Bioscience — advancing better delivery for the medicines of tomorrow. Learn More: b-tv.com/post/lexaria-biosci…

The race is on: major drug companies are competing to develop next-generation oral weight-loss drugs — but effectiveness isn’t enough. Safety and tolerability remain key hurdles. @LexariaBioCorp is tackling the challenge differently. Its patented oral delivery technology improves absorption, helping reduce adverse events by up to 50% in clinical testing. By enhancing how drugs enter the body, rather than altering the active ingredient, Lexaria is unlocking a major opportunity in a multi-billion-dollar market — improving patient experience and long-term adherence. In a rapidly expanding weight-management market, delivery technology may be the missing piece for next-generation oral therapies. Lexaria Bioscience — changing how medicines are delivered, one breakthrough at a time. Learn More: b-tv.com/post/lexaria-biosci…

$LEXX BREAKTHROUGH ALERT: @LexariaBioCorp’s oral DehydraTECH™-tirzepatide achieves comparable levels in bloodstream to injectable Zepbound®—with 47% fewer side effects! 💊⚡ A major breakthrough in diabetes & weight loss treatment. Learn more: morningstar.com/news/accessw… #Biotech #BloodSugar #StocksinNews #StockstoWatch #DiabetesTreatment #PharmaNews

Be Part of the New Biotech Revolution | @LexariaBioCorp Imagine a world where weight loss & diabetes treatments no longer require injections. 🌍💡 Lexaria Bioscience ( $LEXX ) is revolutionizing drug delivery with DehydraTECH™, a patented oral technology designed to enhance absorption—making GLP-1 treatments more accessible, efficient, and convenient for patients worldwide. 🚀 Learn More: b-tv.com/post/lexaria-biosci… #LexariaBioscience #BiotechInnovation #GLP1 #HealthcareRevolution #Diabetes #DrugDelivery

.@LexariaBioCorp's oral delivery technology reduces side effects by 50% for a top diabetes drug—while maintaining powerful results! Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound® Learn more: lexariabioscience.com/2025/0… $LEXX $LEXXW #GLP1 #Biotech #DrugDelivery #BloodSugarCntrol #StocksinNews #StockstoWatch #DiabetesTreatment #PharmaNews #Innovation

The global injectable drug market is skyrocketing, with high-demand GLP-1 weight loss drugs leading the way. By 2025, it's projected to hit $800 billion. | Airing on @CNBC @LexariaBioCorp is changing the game with its patented oral delivery platform, DehydraTECH™, enhancing bloodstream absorption like never before. With a partnership alongside a global pharmaceutical company, Lexaria is paving the future of drug delivery. (NASDAQ: $LEXX) Learn More: b-tv.com/post/lexaria-biosci… #WeightLossDrugs #GLP1 #BloodSugar #DehydraTECH #LexariaBioscience #HealthcareStocks #PharmaceuticalIndustry #StocksinNews

Wall Street Eyes $100B Market Potential for GLP-1 Drugs! | BTV - Business Television featuring @LexariaBioCorp - Airing on @FoxBusiness Breaking into the pharmaceutical industry with a groundbreaking drug or technology can mean big business—and Lexaria Bioscience is on that path. CEO Richard Christopher shared insights on their DehydraTECH™ technology, a game-changing drug delivery enabling technology focused on the GLP-1 marketplace. GLP-1 drugs generated $30 billion in 2023 and are expected to double by 2024, potentially surpassing $100 billion by 2030. DehydraTECH™ significantly enhances the absorption of active pharmaceutical ingredients (APIs), and reduces adverse effects compared to traditional delivery methods. With 46 global patents and results from recent Human Studies showing dramatic improvements, Lexaria is driving innovation. Recently, the company entered a material transfer agreement with a global pharmaceutical partner—marking a pivotal validation of their technology. $LEXX Learn More: b-tv.com/post/lexaria-biosci… #WeightLossDrugs #GLP1 #Pharma #DehydraTECH #LexariaBioscience #HealthcareStocks #PharmaceuticalIndustry #StocksinNews

.@LexariaBioCorp has entered into a Material Transfer Agreement (MTA) with a leading pharmaceutical company to explore the potential of its proprietary DehydraTECH™ technology in a therapeutic area of interest. This new collaboration with Big Pharma aims to assess the versatility and effectiveness of DehydraTECH™ in enhancing drug formulations. The agreement further validates Lexaria's innovation in oral drug delivery and the growing industry interest in DehydraTECH™'s potential for improving treatment efficacy and patient outcomes. Stay tuned as we learn more about the promising developments under this MTA! Learn More: ir.lexariabioscience.com/new… $LEXX $LEXXW #LexariaBioscience #DehydraTECH #GLP1 #diabetes #obesity #biotechinnovation #Biotechnology #biotech #bloodsugar

Lexaria Bioscience | Transforming the Future of GLP-1 Drug Delivery | Airing on Bloomberg, CNBC, and FOX Business Wall Street projects over $100 billion per year in sales for GLP-1 weight loss drugs, despite the challenges of injections. But change is on the horizon! @LexariaBioCorp's  DehydraTECH™ is revolutionizing GLP-1 oral drug delivery, evidencing improved blood sugar control and fewer side effects. Monthly study results are proving the potential of their patented oral delivery method. Discover how Lexaria is transforming the future of weight loss treatment: b-tv.com/post/lexaria-biosci… #Biotech #GLP1 #DrugDelivery #Weightlossdrugs #BloodSugarControl #HealthcareStocks #StocksinNews #StockstoWatch $LEXX

If you missed our latest BTV episode on BNN this weekend, you can catch the full episode on our YT! youtube.com/watch?v=LGvRI5Q_… Ft: @CybinInc $CYBN, @LexariaBioCorp $LEXX, @StageZeroLS $SZLS , @neonmindbio $NEON, and @EmpowerClinics $EPWCF.